Effect of ginsenoside Rg1 on hematopoietic stem cells in treating aplastic anemia in mice via MAPK pathway

Figure 7 Effect of ginsenoside Rg1 on hematopoietic stem cells in the treatment of aplastic anemia in mice through the MAPK pathway. The bone marrow, thymus, and spleen suffered severe damage from cyclophosphamide (CTX), leading to a decrease in hematopoietic cell count. Ginsenoside Rg1 effectively countered the hematopoietic issues in mice, showing superior results compared to the aplastic anemia control group. It reduced cell apoptosis, inflammation factors, and cell cycle disruption caused by CTX. By inhibiting the MAPK signaling pathway, ginsenoside Rg1 greatly improved myelosuppression in mice.